{"content":"<li class=\"n-box-item date-title\" data-end=\"1498190399\" data-start=\"1498104000\" data-txt=\"Monday, December 23, 2019\">Thursday, June 22, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3275179\" data-ts=\"1498167349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275179-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+4.7%</font>. <a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='green'>+4.5%</font>. <a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='green'>+3.3%</font>. <a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='green'>+3.0%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a> <font color='red'>-8.7%</font>. <a href='https://seekingalpha.com/symbol/AMSWA' title='American Software, Inc.'>AMSWA</a> <font color='red'>-6.0%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='red'>-3.8%</font>. <a href='https://seekingalpha.com/symbol/TBPH' title='Theravance Biopharma, Inc.'>TBPH</a> <font color='red'>-3.5%</font>. <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-3.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275179\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$WLB $AGTC $IMDZ - After Hours Gainers / Losers https://seekingalpha.com/news/3275179-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3275179-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275168\" data-ts=\"1498164510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVH\" target=\"_blank\">EVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275168-evolent-launches-stock-offering-shares-slip-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evolent launches stock offering; shares slip 3% after hours</a></h4><ul><li>Evolent Health (NYSE:<a href='https://seekingalpha.com/symbol/EVH' title='Evolent Health'>EVH</a>) is down&nbsp;<font color='red'>3%</font>&nbsp;after hours on robust volume in response to its planned secondary <a href=\"https://seekingalpha.com/pr/16870150-evolent-health-inc-announces-launch-secondary-public-offering-class-common-stock\" target=\"_blank\">public offering</a> of 4.5M shares of common stock. Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275168\" data-linked=\"Evolent launches stock offering; shares slip 3% after hours\" data-tweet=\"$EVH - Evolent launches stock offering; shares slip 3% after hours https://seekingalpha.com/news/3275168-evolent-launches-stock-offering-shares-slip-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3275168-evolent-launches-stock-offering-shares-slip-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275167\" data-ts=\"1498164138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONC\" target=\"_blank\">SONC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275167-sonicminus-2_9-amid-declining-store-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sonic -2.9% amid declining same-store sales</a></h4><ul>   <li>Sonic (NASDAQ:<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a>) is <font color='red'>off 2.9%</font> after hours after revenue slipped 25% Y/Y and missed expectations amid a refocus on franchising in the company's <a href=\"https://seekingalpha.com/news/3275147-sonic-beats-0_02-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li>    <li>EPS was flat on a non-GAAP basis (at $0.43) but rose 42% on a GAAP basis, to $0.44.</li>    <li>Same-store sales fell 1.2% (down 1.1% at franchises, down 3.2% at company drive-ins).</li>    <li>But the results showed improvement in underlying sales and store profits, CEO Cliff Hudson says. \"Despite continued sluggish traffic, we are working to improve same-store sales this summer and beyond, with new product news, targeted value and quality customer service.\"</li>    <li>Drive-in margins increased by 40 basis points.</li>    <li>For the full year, the company still expects EPS down 2-5% as same-store sales fall about 2.5% systemwide. It's forecasting capex of $46M-$48M and free cash flow of $55M-$60M.</li>    <li><a href=\"http://ir.sonicdrivein.com/\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16870076-sonic-reports-improved-sales-trend-fiscal-third-quarter\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3275167\" data-linked=\"Sonic -2.9% amid declining same-store sales\" data-tweet=\"$SONC - Sonic -2.9% amid declining same-store sales https://seekingalpha.com/news/3275167-sonicminus-2_9-amid-declining-store-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3275167-sonicminus-2_9-amid-declining-store-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275163\" data-ts=\"1498163514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275163-fda-rejects-pfizers-marketing-application-for-epogen-biosimilar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects Pfizer&#39;s marketing application for Epogen biosimilar</a></h4><ul><li>Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) receives a Complete Response Letter &#40;CRL&#41; from the FDA regarding its marketing application seeking approval of its biosimilar to Amgen's (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) Epogen (epoetin alfa). The CRL relates to a warning letter issued in February after an on-site inspection of the company's McPherson, KS facility, a potential manufacturing site for the product.</li><li>The company says it is working with the agency to address the issues.</li><li>Source: Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3275163\" data-linked=\"FDA rejects Pfizer&#39;s marketing application for Epogen biosimilar\" data-tweet=\"$PFE $PFE $AMGN - FDA rejects Pfizer&#39;s marketing application for Epogen biosimilar https://seekingalpha.com/news/3275163-fda-rejects-pfizers-marketing-application-for-epogen-biosimilar?source=tweet\" data-url=\"https://seekingalpha.com/news/3275163-fda-rejects-pfizers-marketing-application-for-epogen-biosimilar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275157\" data-ts=\"1498162938\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBBY\" target=\"_blank\">BBBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275157-bed-bath-beyond-crumbles-after-earnings-miss-comp-sales-fall-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bed Bath &amp; Beyond crumbles after earnings miss; comp sales fall 2%</a></h4><ul><li>From the earnings PR: \"The&nbsp;Company did experience increased softness in transactions in stores, as well as higher net-direct-to-customer shipping expense, coupon expense, and advertising costs ...&nbsp;It remains to be seen whether these challenges were more pronounced in, or unique to, the first quarter due to the smaller sales base in this period, and/or a later start to the summer selling period.\"</li><li>Comp sales fell about 2% Y/Y.</li><li><a href=\"http://www.bedbathandbeyond.com\" target=\"_blank\">Conference call coming at 5 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3275155-bed-bath-and-beyond-misses-0_13-misses-revenue\" target=\"_blank\">Bed Bath &amp; Beyond misses by $0.13, misses on revenue</a> (June 22)</li><li><a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>&nbsp;<font color='red'>-9%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3275157\" data-linked=\"Bed Bath &amp; Beyond crumbles after earnings miss; comp sales fall 2%\" data-tweet=\"$BBBY - Bed Bath &amp; Beyond crumbles after earnings miss; comp sales fall 2% https://seekingalpha.com/news/3275157-bed-bath-beyond-crumbles-after-earnings-miss-comp-sales-fall-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3275157-bed-bath-beyond-crumbles-after-earnings-miss-comp-sales-fall-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275152\" data-ts=\"1498162583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNX\" target=\"_blank\">SNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275152-synnex-beats-0_29-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synnex beats by $0.29, beats on revenue</a></h4><ul><li>Synnex (NYSE:<a href='https://seekingalpha.com/symbol/SNX' title='SYNNEX Corporation'>SNX</a>): Q2 EPS of $2.08 <font color='green'>beats by $0.29</font>.</li><li>Revenue of $3.94B (+16.6% Y/Y) <font color='green'>beats by $220M</font>.</li><li>Shares <font color='green'>+1.07%</font>.</li><li><a href='https://seekingalpha.com/pr/16870105-synnex-corporation-reports-fiscal-2017-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3275152\" data-linked=\"Synnex beats by $0.29, beats on revenue\" data-tweet=\"$SNX - Synnex beats by $0.29, beats on revenue https://seekingalpha.com/news/3275152-synnex-beats-0_29-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3275152-synnex-beats-0_29-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275137\" data-ts=\"1498160303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWBO\" target=\"_blank\">NWBO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275137-northwest-bio-closes-convertible-debt-deal-completes-payoff-of-11m-in-bonds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northwest Bio closes convertible debt deal, completes payoff of $11M in bonds</a></h4><ul><li>Northwest Biotherapeutics (<a href='https://seekingalpha.com/symbol/NWBO' title='Northwest Biotherapeutics, Inc.'>OTCQB:NWBO</a>) <a href=\"https://seekingalpha.com/pr/16869789-nwbio-closes-3-year-convertible-debt-exchange-financing-completes-payoff-last-5-million-2014\" target=\"_blank\">reports </a>that it has closed a convertible debt exchange and financing transaction with a non-affiliated investor and has finished paying off the last $5M of principal and $175K of interest from a 2014 bond offering. The deal completes its payoff of $11M in bonds.</li><li>Under terms of the exchange, 50% will be convertible at $0.25/share, 25% at $0.50/share and 25% at $1.00/share. The debt is secured by company-owned property in the UK.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275137\" data-linked=\"Northwest Bio closes convertible debt deal, completes payoff of $11M in bonds\" data-tweet=\"$NWBO - Northwest Bio closes convertible debt deal, completes payoff of $11M in bonds https://seekingalpha.com/news/3275137-northwest-bio-closes-convertible-debt-deal-completes-payoff-of-11m-in-bonds?source=tweet\" data-url=\"https://seekingalpha.com/news/3275137-northwest-bio-closes-convertible-debt-deal-completes-payoff-of-11m-in-bonds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275136\" data-ts=\"1498160207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WP\" target=\"_blank\">WP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275136-buy-dip-in-vantiv-kbw\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buy the dip in Vantiv - KBW</a></h4><ul><li>Concern about exposure to large retailers and supermarkets is overblown, says analyst Steven Kwok, upping Vantiv (VNTV <font color='green'>+3.8%</font>) to Outperform from Market Perform. Shares fell nearly 4% on Friday after Amazon's deal for Whole Foods.</li><li>Strong growth is possible despite said exposure, says Kwok, and a large acquisition is also a possibility.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275136\" data-linked=\"Buy the dip in Vantiv - KBW\" data-tweet=\"$WP - Buy the dip in Vantiv - KBW https://seekingalpha.com/news/3275136-buy-dip-in-vantiv-kbw?source=tweet\" data-url=\"https://seekingalpha.com/news/3275136-buy-dip-in-vantiv-kbw\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275134\" data-ts=\"1498159841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275134-sears-to-close-20-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears to close 20 more stores</a></h4><ul>   <li>Sears Holdings (<a href=\"http://seekingalpha.com/symbol/SHLD\" target=\"_blank\">SHLD</a> <font color='green'>+7%</font>) is preparing to <a href=\"http://www.businessinsider.com/sears-is-closing-more-stores-2017-6\" target=\"_blank\">close 20 more stores</a> in the United States.</li>    <li>That's on top of 245 closings already announced, employees told Business Insider, and will bring the company's store count down to about 1,180.</li>    <li>The new closings come in a number of states and a few large cities, including Chicago; San Diego; Houston; Toledo, Ohio; and Albany, N.Y.</li>    <li>Earlier, Sears Canada (<a href=\"http://seekingalpha.com/symbol/SRSC\" target=\"_blank\">SRSC</a> <font color='red'>-19.9%</font>) announced it would close a quarter of its stores (59 locations) as part of <a href=\"https://seekingalpha.com/news/3274999-sears-canada-shares-halted\" target=\"_blank\">court-ordered restructuring</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275134\" data-linked=\"Sears to close 20 more stores\" data-tweet=\"$SHLDQ $SHLDQ $SRSC - Sears to close 20 more stores https://seekingalpha.com/news/3275134-sears-to-close-20-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3275134-sears-to-close-20-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275133\" data-ts=\"1498159416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275133-celsion-backs-away-from-proposed-direct-equity-offering-shares-up-24-on-m-prospects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion backs away from proposed direct equity offering; shares up 24% on M&amp;A prospects</a></h4><ul><li>Celsion (<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+23.8%</font>) has <a href=\"https://seekingalpha.com/pr/16870008-celsion-corporation-announces-cancellation-registered-direct-offering\" target=\"_blank\">canceled </a>its previously announced direct equity offering to institutional investors. Quick-trigger traders are taking positions in the hopes of a takeout, but it may only be a prelude to another financing round.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274243-celsion-inks-5_4m-capital-raise-via-direct-placement-shares-24-percent\" target=\"_blank\">Celsion inks $5.4M capital raise via direct placement; shares down 24%</a> (June 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275133\" data-linked=\"Celsion backs away from proposed direct equity offering; shares up 24% on M&amp;A prospects\" data-tweet=\"$CLSN - Celsion backs away from proposed direct equity offering; shares up 24% on M&amp;A prospects https://seekingalpha.com/news/3275133-celsion-backs-away-from-proposed-direct-equity-offering-shares-up-24-on-m-prospects?source=tweet\" data-url=\"https://seekingalpha.com/news/3275133-celsion-backs-away-from-proposed-direct-equity-offering-shares-up-24-on-m-prospects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275132\" data-ts=\"1498158861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PED\" target=\"_blank\">PED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275132-pedevco-ends-merger-gom-holdings-gets-interest-from-new-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pedevco ends merger with GOM Holdings, gets interest from new group</a></h4><ul><li>Pedevco (<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='green'>+37.7%</font>) says it <a href=\"https://seekingalpha.com/filing/3602145\" target=\"_blank\">terminated its pending merger</a> with GOM Holdings,&nbsp; a deal which has been delayed for more than a year while GOM's assets continue to be subject to bankruptcy proceedings.</li><li>PED says it has entered into a new non-binding letter of intent with a Hong Kong-based  investor group that may fund development of the company's oil and gas assets and restructuring  its debt.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275132\" data-linked=\"Pedevco ends merger with GOM Holdings, gets interest from new group\" data-tweet=\"$PED - Pedevco ends merger with GOM Holdings, gets interest from new group https://seekingalpha.com/news/3275132-pedevco-ends-merger-gom-holdings-gets-interest-from-new-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3275132-pedevco-ends-merger-gom-holdings-gets-interest-from-new-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275128\" data-ts=\"1498158004\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275128-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+14%</font>. COOL <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SUNW' title='Sunworks, Inc.'>SUNW</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SFUN' title='Fang Holdings Ltd. ADS'>SFUN</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275128\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$SNCR $SPWR $TCCO - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3275128-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3275128-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275121\" data-ts=\"1498156217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCR\" target=\"_blank\">SNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275121-synchronoss-requests-lender-extension-quells-cloud-concerns-shares-up-nearly-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchronoss requests lender extension, quells cloud concerns; shares up nearly 20%</a></h4><ul><li>        Synchronoss (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) <a href=\"https://seekingalpha.com/filing/3602036\" target=\"_blank\">asks</a> lenders for more time to deliver Q1 financial statements as required.</li><li>               The company says the previously announced restatement of FY15 and FY16 statements has taken longer than expected and won&rsquo;t finish before the end of the 30-day grace period. &nbsp;Synchronoss asks for an additional 60 days.&nbsp;</li><li>               Agreeing lenders will receive 25 bps of fee payable on closing and the margin on the term loan will increase by the same amount.</li><li>               Meanwhile, Synchronoss&rsquo; comments during the lender presentation have eased concerns about the company's cloud business.&nbsp;</li><li>According to <a href=\"http://thefly.com/news.php\" target=\"_blank\">The Fly,</a> JPMorgan analyst Sterling Auty says the company listing AT&amp;T and Verizon as current cloud customers should quell any cloud concerns.&nbsp;&nbsp;&nbsp;</li><li>Synchronoss shares are&nbsp;<font color='green'>up 19.81%</font>. .</li></ul><div class=\"tiny-share-widget\" data-id=\"3275121\" data-linked=\"Synchronoss requests lender extension, quells cloud concerns; shares up nearly 20%\" data-tweet=\"$SNCR - Synchronoss requests lender extension, quells cloud concerns; shares up nearly 20% https://seekingalpha.com/news/3275121-synchronoss-requests-lender-extension-quells-cloud-concerns-shares-up-nearly-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3275121-synchronoss-requests-lender-extension-quells-cloud-concerns-shares-up-nearly-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275117\" data-ts=\"1498154685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDC\" target=\"_blank\">BDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275117-belden-lower-cl-king-initiates-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Belden lower as CL King initiates at Neutral</a></h4><ul>   <li>Belden (NYSE:<a href='https://seekingalpha.com/symbol/BDC' title='Belden Inc.'>BDC</a>) is <font color='red'>off 1.6%</font> following news that CL King launched coverage of the stock at Neutral.</li>    <li>That makes for a fourth firm at Neutral/Hold, vs. at least four with Buy ratings. JPMorgan initiated coverage at Neutral in February, with a $76 price target (which would be 3.4% upside from today's price).</li>    <li>Shares are also <font color='red'>down 1.6%</font> in 2017. They've <font color='green'>gained 15.9%</font> over the past 12 months, however.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275117\" data-linked=\"Belden lower as CL King initiates at Neutral\" data-tweet=\"$BDC - Belden lower as CL King initiates at Neutral https://seekingalpha.com/news/3275117-belden-lower-cl-king-initiates-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3275117-belden-lower-cl-king-initiates-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275116\" data-ts=\"1498154442\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275116-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/NBLX' title='Noble Midstream Partners LP'>NBLX</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/AXAS' title='Abraxas Petroleum Corporation'>AXAS</a> <font color='red'>-7%</font>. SGY <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/REXX' title='Rex Energy Corporation'>REXX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/KLDX' title='Klondex Mines Ltd.'>KLDX</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275116\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$AMRS $CRC $ERN - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3275116-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3275116-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275111\" data-ts=\"1498152878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275111-snap-map-feature-powered-250m-plus-purchase-of-zenly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap Map feature powered by $250M-plus purchase of Zenly</a></h4><ul>   <li>Snap (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color='green'>+2.7%</font>) acquired France's social-mapping app firm Zenly to feed its new mapping feature.</li>    <li>After reports that Snap was working on <a href=\"https://seekingalpha.com/news/3274509-report-snap-nearing-release-mapping-feature\" target=\"_blank\">adding location sensitivity</a> to its app, the company launched Snap Map, which <a href=\"https://venturebeat.com/2017/06/22/inside-frances-zenly-the-social-mapping-app-that-was-just-bought-by-snap/\" target=\"_blank\">looked like a Zenly clone</a> (for good reason, it turns out).</li>    <li>The deal closed in late May, and is mostly cash and <a href=\"https://techcrunch.com/2017/06/21/snapchat-buys-zenly/\" target=\"_blank\">lands between $250M-$350M</a>, according to TechCrunch.</li>    <li>The Zenly operation will run independently, similar to how Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) runs Instagram.</li>    <li>While Zenly previously ran constant location services in the background, Snap Map pulls your location when you open the app, and shows where your friends are Snapping.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3275111\" data-linked=\"Snap Map feature powered by $250M-plus purchase of Zenly\" data-tweet=\"$FB $FB $SNAP - Snap Map feature powered by $250M-plus purchase of Zenly https://seekingalpha.com/news/3275111-snap-map-feature-powered-250m-plus-purchase-of-zenly?source=tweet\" data-url=\"https://seekingalpha.com/news/3275111-snap-map-feature-powered-250m-plus-purchase-of-zenly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275108\" data-ts=\"1498151205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFSI\" target=\"_blank\">PFSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275108-pennymac-financial-services-up-6-after-buyback-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PennyMac Financial Services up 6% after buyback plan</a></h4><ul><li>The company last night <a href=\"https://seekingalpha.com/pr/16868814-pennymac-financial-services-inc-announces-50-million-stock-repurchase-program\" target=\"_blank\">announced its intent </a>to buy back up to $50M of common stock. CEO Stan Kurland says this shouldn't impinge on his firm's mortgage banking activities or potential MSR acquisitions.</li><li>At the current price, $50M would be enough to repurchase nearly 13% of the float.</li><li><a href='https://seekingalpha.com/symbol/PFSI' title='PennyMac Financial Services'>PFSI</a>&nbsp;<font color='green'>+6.1%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3275108\" data-linked=\"PennyMac Financial Services up 6% after buyback plan\" data-tweet=\"$PFSI - PennyMac Financial Services up 6% after buyback plan https://seekingalpha.com/news/3275108-pennymac-financial-services-up-6-after-buyback-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3275108-pennymac-financial-services-up-6-after-buyback-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275107\" data-ts=\"1498150867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275107-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MN' title='Manning & Napier'>MN</a> <font color='green'>+7%</font>.<a href='https://seekingalpha.com/symbol/PFSI' title='PennyMac Financial Services'>PFSI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GTS' title='Triple-S Management Corporation'>GTS</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/RM' title='Regional Management Corp.'>RM</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/JCAP' title='Jernigan Capital'>JCAP</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275107\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$PN $MN $PFSI - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3275107-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3275107-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275103\" data-ts=\"1498150109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275103-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ENOC' title='EnerNOC, Inc.'>ENOC</a> <font color='green'>+41%</font>. <a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+15%</font>. VRX <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TOO' title='Teekay Offshore Partners L.P.'>TOO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/DCTH' title='Delcath Systems, Inc.'>OTC:DCTH</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/MGEN' title='Miragen Therapeutics, Inc.'>MGEN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/FLGT' title='Fulgent Genetics'>FLGT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/JCAP' title='Jernigan Capital'>JCAP</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275103\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ENOC $DMPI $NVIV - Midday Gainers / Losers https://seekingalpha.com/news/3275103-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3275103-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275101\" data-ts=\"1498149464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275101-cnbc-nordstrom-family-moving-ahead-finding-p-e-buyer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC: Nordstrom family moving ahead with finding P-E buyer</a></h4><ul>     <li>The Nordstrom family is moving ahead with <a href=\"http://www.cnbc.com/2017/06/22/nordstrom-family-private-equity-buyer.html\" target=\"_blank\">finding a private equity buyer</a> for the department store chain, forming a special committee and hiring advisers including bankers, lawyers and a PR firm, CNBC reports.</li>     <li>JWN said earlier this month that the family had begun to explore a going-private deal, though they had not yet made a proposal; shares are up 13% since the closing price on June 7, the day before the company <a href=\"https://seekingalpha.com/news/3272381-nordstrom-go-private-exploration-jolts-sector\" target=\"_blank\">announced a possible deal</a>.</li>     <li>The Nordstrom family owns ~30% of the company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275101\" data-linked=\"CNBC: Nordstrom family moving ahead with finding P-E buyer\" data-tweet=\"CNBC: Nordstrom family moving ahead with finding P-E buyer https://seekingalpha.com/news/3275101-cnbc-nordstrom-family-moving-ahead-finding-p-e-buyer?source=tweet\" data-url=\"https://seekingalpha.com/news/3275101-cnbc-nordstrom-family-moving-ahead-finding-p-e-buyer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275099\" data-ts=\"1498148854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275099-drug-stocks-rally-on-gop-draft-of-healthcare-bill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drug stocks rally on GOP draft of healthcare bill</a></h4><ul><li>Money flow into drug makers has ramped up after the release of Republicans' draft healthcare bill and fears subside that there will be any significant headwinds to future price increases.</li><li>(VRX <font color='green'>+12%</font>)(<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='green'>+2.8%</font>)(<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+1%</font>)(<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+4.7%</font>)(<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='green'>+2.2%</font>)(<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='green'>+2.6%</font>)(<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='green'>+1.8%</font>)(<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+4%</font>)(<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+1.8%</font>)(<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='green'>+1.6%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='green'>+1.8%</font>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+5.4%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+1%</font>)(<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+0.7%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275099\" data-linked=\"Drug stocks rally on GOP draft of healthcare bill\" data-tweet=\"$BHC $BHC $ABBV - Drug stocks rally on GOP draft of healthcare bill https://seekingalpha.com/news/3275099-drug-stocks-rally-on-gop-draft-of-healthcare-bill?source=tweet\" data-url=\"https://seekingalpha.com/news/3275099-drug-stocks-rally-on-gop-draft-of-healthcare-bill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>119&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275096\" data-ts=\"1498147661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFN\" target=\"_blank\">INFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275096-infineraplus-6-b-riley-joins-upgrade-parade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinera +6% as B. Riley joins upgrade parade</a></h4><ul>   <li>Infinera (NASDAQ:<a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a>) is <font color='green'>up 6%</font> and at its highest point since mid-February after an upgrade to Buy from B. Riley.</li>    <li>Volume is up recently according to supplier checks, says analyst David Kang, and new products are set to ramp up in the second half.</li>    <li>Kang says the company's well positioned in long haul, metro and data center interconnect markets as well.</li>    <li>He's boosted his price target to $14 from $9.50, implying 18% upside from today's price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275096\" data-linked=\"Infinera +6% as B. Riley joins upgrade parade\" data-tweet=\"$INFN - Infinera +6% as B. Riley joins upgrade parade https://seekingalpha.com/news/3275096-infineraplus-6-b-riley-joins-upgrade-parade?source=tweet\" data-url=\"https://seekingalpha.com/news/3275096-infineraplus-6-b-riley-joins-upgrade-parade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275093\" data-ts=\"1498147395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275093-mylan-shareholders-back-board-thumbs-down-on-executive-pay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mylan shareholders back board but thumbs down on executive pay</a></h4><ul><li>Reuters <a href=\"http://www.reuters.com/article/us-mylan-meeting-idUSKBN19D1QT?il=0\" target=\"_blank\">reports </a>that Mylan NV (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+2.1%</font>) shareholders voted to re-elect the board during its Annual Meeting but voted against a measure to approve its executive compensation plan. Stockholders rebelled after choking on Chairman Robert Coury's almost $100M package disclosed earlier this year.</li><li>A number of institutional investors, including the proxy advisor ISS, urged shareholders to vote against re-electing the board to demonstrate their dissatisfaction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275093\" data-linked=\"Mylan shareholders back board but thumbs down on executive pay\" data-tweet=\"$MYL - Mylan shareholders back board but thumbs down on executive pay https://seekingalpha.com/news/3275093-mylan-shareholders-back-board-thumbs-down-on-executive-pay?source=tweet\" data-url=\"https://seekingalpha.com/news/3275093-mylan-shareholders-back-board-thumbs-down-on-executive-pay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275091\" data-ts=\"1498147270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275091-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/WILC' title='G. Willi-Food International, Ltd.'>WILC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/STRT' title='Strattec Security Corporation'>STRT</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a> <font color='red'>-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275091\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$WILC $VOXX $REED - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3275091-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3275091-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275088\" data-ts=\"1498146540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYH\" target=\"_blank\">CYH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275088-hospitals-up-on-gop-healthcare-plan-aimed-stabilizing-insurance-exchanges\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hospitals up on GOP healthcare plan aimed at stabilizing insurance exchanges</a></h4><ul><li>Buying has accelerated in hospital operators as investors internalize the details of Republicans' <a href=\"https://www.budget.senate.gov/imo/media/doc/SENATEHEALTHCARE.pdf\" target=\"_blank\">healthcare bill</a>. A key driver is the $50B to stabilize insurance exchanges.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='green'>+9.9%</font>)(<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+7.9%</font>)(<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='green'>+2%</font>)(<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a> <font color='green'>+4.2%</font>)(<a href='https://seekingalpha.com/symbol/LPNT' title='LifePoint Health, Inc.'>LPNT</a> <font color='green'>+3.3%</font>)(<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='green'>+7.6%</font>)(<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a> <font color='green'>+2.7%</font>)(<a href='https://seekingalpha.com/symbol/SEM' title='Select Medical Holdings Corporation'>SEM</a> <font color='green'>+2.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275088\" data-linked=\"Hospitals up on GOP healthcare plan aimed at stabilizing insurance exchanges\" data-tweet=\"$CYH $CYH $THC - Hospitals up on GOP healthcare plan aimed at stabilizing insurance exchanges https://seekingalpha.com/news/3275088-hospitals-up-on-gop-healthcare-plan-aimed-stabilizing-insurance-exchanges?source=tweet\" data-url=\"https://seekingalpha.com/news/3275088-hospitals-up-on-gop-healthcare-plan-aimed-stabilizing-insurance-exchanges\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275084\" data-ts=\"1498146112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOPS\" target=\"_blank\">TOPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275084-top-ships-to-effect-1-forminus-15-reverse-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Top Ships to effect 1-for-15 reverse split</a></h4><ul>     <li>Top Ships (<a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='red'>-14.6%</font>) discloses a <a href=\"https://seekingalpha.com/filing/3601685\" target=\"_blank\">1-for-15 reverse split</a> of the company's common stock, effective at tomorrow's open.</li><li>The move will reduce the number of outstanding shares to ~1.4M from 21.6M.</li><li>TOPS implemented a 1-for-20 reverse stock split just <a href=\"https://seekingalpha.com/filing/3542730\" target=\"_blank\">six weeks ago</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275084\" data-linked=\"Top Ships to effect 1-for-15 reverse split\" data-tweet=\"$TOPS - Top Ships to effect 1-for-15 reverse split https://seekingalpha.com/news/3275084-top-ships-to-effect-1-forminus-15-reverse-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3275084-top-ships-to-effect-1-forminus-15-reverse-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275082\" data-ts=\"1498145906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATCEY\" target=\"_blank\">ATCEY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275082-report-charter-interested-in-buying-cox-communications\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Charter interested in buying Cox Communications</a></h4><ul>    <li>Fresh from swallowing Time Warner Cable and Bright House, Charter (<a href=\"http://seekingalpha.com/symbol/CHTR\" target=\"_blank\">CHTR</a> <font color='green'>+0.9%</font>) is now linked to chatter about another mega-buyout: of rival Cox Communications.</li>    <li>\"Tom <a href=\"http://nypost.com/2017/06/21/cable-giants-in-talks-for-yet-another-high-profile-merger/\" target=\"_blank\">wants to buy Cox</a>,\" a source tells the New York Post about Charter chief Tom Rutledge.</li>    <li>Privately owned Cox is the country's third-largest cable company, behind Comcast and Charter, with 6.2M customers; it's spurned other purchase overtures to date.</li>    <li>&ldquo;Cox has been very clear and consistent that we are not for sale and, in fact, we&rsquo;re aggressively investing in our network, products and strategic partnerships and investments of our own,&rdquo; says Cox's Todd Smith.</li>    <li>But if Cox has a change of heart, it would likely see interest not only from Charter but from Comcast (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='red'>-0.1%</font>) and Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='green'>+0.3%</font>), not to mention Altice (<a href='https://seekingalpha.com/symbol/ATCEY' title='ALTICE S A ADR'>OTCPK:ATCEY</a>), which has freshly launched an IPO of its USA operation (<a href=\"http://seekingalpha.com/symbol/ATUS\" target=\"_blank\">ATUS</a> <font color='green'>+5.4%</font>).</li>    <li>Buying TWC and Bright House cost Charter $67.1B.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275082\" data-linked=\"Report: Charter interested in buying Cox Communications\" data-tweet=\"$ATCEY $ATCEY $CHTR - Report: Charter interested in buying Cox Communications https://seekingalpha.com/news/3275082-report-charter-interested-in-buying-cox-communications?source=tweet\" data-url=\"https://seekingalpha.com/news/3275082-report-charter-interested-in-buying-cox-communications\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275078\" data-ts=\"1498145669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCAP\" target=\"_blank\">JCAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275078-jernigan-capital-down-7-after-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jernigan Capital down 7% after share sale</a></h4><ul><li>Jernigan (NYSE:<a href='https://seekingalpha.com/symbol/JCAP' title='Jernigan Capital'>JCAP</a>) upsized <a href=\"https://seekingalpha.com/pr/16869573-jernigan-capital-inc-announces-pricing-upsized-public-offering-common-stock\" target=\"_blank\">its capital raise to</a> 3.5M shares from 3M. The sale priced at $22 each. The underwriters have an option to buy another 525K shares at that price.</li><li>JCAP is<font color='red'> lower by 7.35%&nbsp;</font>to $22.48 on volume of 1.6M shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275078\" data-linked=\"Jernigan Capital down 7% after share sale\" data-tweet=\"$JCAP - Jernigan Capital down 7% after share sale https://seekingalpha.com/news/3275078-jernigan-capital-down-7-after-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3275078-jernigan-capital-down-7-after-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275077\" data-ts=\"1498145332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275077-kroger-re-ups-buyback-boosts-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kroger re-ups buyback, boosts dividend</a></h4><ul><li>Does this mean Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='red'>-0.4%</font>) won't be launching a competing bid for Whole Foods?</li><li>Alongside <a href=\"https://seekingalpha.com/news/3275074-kroger-declares-0_125-dividend\" target=\"_blank\">a boost in the</a> annual payout to $0.50 from $0.48, Kroger approves a $1B buyback program to replace the now-exhausted prior one.</li><li>Shares have gained since the announcement, but remain in the red on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275077\" data-linked=\"Kroger re-ups buyback, boosts dividend\" data-tweet=\"$KR - Kroger re-ups buyback, boosts dividend https://seekingalpha.com/news/3275077-kroger-re-ups-buyback-boosts-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3275077-kroger-re-ups-buyback-boosts-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275072\" data-ts=\"1498144097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBPB\" target=\"_blank\">PBPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275072-activist-takes-aim-potbelly-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Activist takes aim at Potbelly - Reuters</a></h4><ul><li>An owner of 4% of the stock, Ancora Advisors has sent a letter to the board <a href=\"http://www.reuters.com/article/us-potbelly-ancora-idUSKBN19D1VX\" target=\"_blank\">urging certain</a> strategy changes, or, failing that, a sale of the company.</li><li><a href='https://seekingalpha.com/symbol/PBPB' title='Potbelly Corporation'>PBPB</a><font color='green'> +1.6%</font>&nbsp;on the news.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3226573-reuters-del-friscos-restaurant-activists-might-push-sale\" target=\"_blank\">Reuters: Del Frisco's Restaurant activists might push for sale</a> (Nov. 22, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275072\" data-linked=\"Activist takes aim at Potbelly - Reuters\" data-tweet=\"$PBPB - Activist takes aim at Potbelly - Reuters https://seekingalpha.com/news/3275072-activist-takes-aim-potbelly-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3275072-activist-takes-aim-potbelly-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275071\" data-ts=\"1498143845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YPF\" target=\"_blank\">YPF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275071-ypf-s-stock-plunge-offers-buying-opportunity-morgan-stanley-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YPF\u2019s stock plunge offers buying opportunity, Morgan Stanley says</a></h4><ul>     <li>The plunge in YPF&rsquo;s (<a href='https://seekingalpha.com/symbol/YPF' title='YPF Sociedad Anonima'>YPF</a> <font color='green'>+4%</font>) stock price is unwarranted and offers a \"buy on weakness\" opportunity, Morgan Stanley analysts say.</li>     <li><a href=\"https://seekingalpha.com/news/3274715-argentine-adrs-rough-session-msci-decision\" target=\"_blank\">MSCI's negative decision on Argentina</a> was a technical event, and hydrocarbon prices in the country will remain on healthy levels throughout 2017, the firm says, adding that YPF's valuation is attractive as it trades at a discount to large-cap integrated oil stocks and to global oil stocks.</li>     <li>YPF ADRs fell as much as 8% yesterday before finishing 5% lower after MSCI refused to upgrade Argentina to emerging from frontier market  status.</li><li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275071\" data-linked=\"YPF\u2019s stock plunge offers buying opportunity, Morgan Stanley says\" data-tweet=\"$YPF - YPF\u2019s stock plunge offers buying opportunity, Morgan Stanley says https://seekingalpha.com/news/3275071-ypf-s-stock-plunge-offers-buying-opportunity-morgan-stanley-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3275071-ypf-s-stock-plunge-offers-buying-opportunity-morgan-stanley-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275043\" data-ts=\"1498143648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275043-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XBIT' title='Xbiotech'>XBIT</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/QURE' title='uniQure N.V.'>QURE</a> <font color='green'>+9%</font>. VRX <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SBPH' title='Spring Bank Pharmaceuticals'>SBPH</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275043\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$XBIT $ABEO $DMPI - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3275043-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3275043-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275064\" data-ts=\"1498143135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275064-regeneron-clarifies-canakinumab-royalty-deal-novartis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regeneron clarifies canakinumab royalty deal with Novartis</a></h4><ul><li>Novartis' (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+4.4%</font>) <a href=\"http://www.nasdaq.com/article/surprise-win-for-antiinflammatory-heart-drug-boosts-novartis-20170622-00106\" target=\"_blank\">announcement</a> of positive late-stage results for canakinumab in reducing CV risk prompts Regeneron Pharmaceuticals (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+2.5%</font>) to issue a <a href=\"https://seekingalpha.com/pr/16869523-regeneron-details-royalty-agreement-novartis-canakinumab-acz885\" target=\"_blank\">statement </a>clarifying its royalty rights to the candidate if approved for sale as specified in their <a href=\"http://investor.regeneron.com/releasedetail.cfm?releaseid=393892\" target=\"_blank\">2009 agreement.</a></li><li>Regeneron's royalty starts at 4% and ramps to 15% when annual sales of canakinumab exceed $1.5B.</li><li>Novartis currently markets canakinumab under the brand name <a href=\"http://ilaris.com/index.jsp\" target=\"_blank\">ILARIS </a>for the treatment of Juvenile Idiopathic Arthritis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275064\" data-linked=\"Regeneron clarifies canakinumab royalty deal with Novartis\" data-tweet=\"$NVS $NVS $REGN - Regeneron clarifies canakinumab royalty deal with Novartis https://seekingalpha.com/news/3275064-regeneron-clarifies-canakinumab-royalty-deal-novartis?source=tweet\" data-url=\"https://seekingalpha.com/news/3275064-regeneron-clarifies-canakinumab-royalty-deal-novartis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275063\" data-ts=\"1498143032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMX\" target=\"_blank\">KMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275063-carmaxplus-4_5-rbc-upgrades-seeing-positive-momentum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CarMax +4.5% as RBC upgrades, seeing positive momentum</a></h4><ul><li>CarMax (<a href='https://seekingalpha.com/symbol/KMX' title='CarMax Group'>KMX</a> <font color='green'>+4.5%</font>) is off to a strong start after RBC <a href=\"https://www.thestreet.com/story/14191399/1/carmax-stock-rises-on-rbc-upgrade-sees-positive-momentum.html\" target=\"_blank\">upgrades</a> shares to Outperform from Sector Perform with a $69 price target, raised from $63, citing positive momentum despite declining used car values.</li><li>RBC notes that KMX's comps have continued to outpace expectations because of falling used vehicle values - making \"used\" more attractive vs.  \"new\" - and significant improvements in search engine optimization, trends the firm believe should continue.</li><li>The firm also says recent data has  helped ease prior concerns regarding unit margins and CAF loss  rates.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275063\" data-linked=\"CarMax +4.5% as RBC upgrades, seeing positive momentum\" data-tweet=\"$KMX - CarMax +4.5% as RBC upgrades, seeing positive momentum https://seekingalpha.com/news/3275063-carmaxplus-4_5-rbc-upgrades-seeing-positive-momentum?source=tweet\" data-url=\"https://seekingalpha.com/news/3275063-carmaxplus-4_5-rbc-upgrades-seeing-positive-momentum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275060\" data-ts=\"1498142504\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAYO\" target=\"_blank\">ZAYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275060-zayo-sales-chief-leaving-after-month-to-rejoin-level-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zayo sales chief leaving after a month to rejoin Level 3</a></h4><ul>   <li>With CenturyLink naming <a href=\"https://seekingalpha.com/news/3275051-centurylink-sets-operations-structure-ahead-level-3-merger\" target=\"_blank\">presidents of its operational units</a>, Zayo Group (NYSE:<a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a>) group is losing its sales leader.</li><li>Ed Morche is resigning from Zayo after just a month to rejoin Level 3 Communications, and take over the strategic enterprise, federal government and state government at CenturyLink as it completes its merger with Level 3.</li>    <li>ZAYO Shares are <font color='red'>down 2%</font>.</li><li>Morche's leaving due to \"enhanced compensation\" and expanded responsibilities at the merged CenturyLink/Level 3.</li>    <li>During his short tenure, Morche was <a href=\"https://www.streetinsider.com/Corporate+News/Zayo+Group+%28ZAYO%29+Says+Sales+Leader+Edward+Morche+Resigns+to+Rejoin+Level+3+Communications%3B+Confident+in+Positive+Net+Bookings+Momentum/13035399.html\" target=\"_blank\">upbeat about Zayo's sales</a>, the company says, expecting positive net bookings momentum.</li>    <li>Max Clauson will resume overall leadership of sales at Zayo.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275060\" data-linked=\"Zayo sales chief leaving after a month to rejoin Level 3\" data-tweet=\"$ZAYO - Zayo sales chief leaving after a month to rejoin Level 3 https://seekingalpha.com/news/3275060-zayo-sales-chief-leaving-after-month-to-rejoin-level-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3275060-zayo-sales-chief-leaving-after-month-to-rejoin-level-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275059\" data-ts=\"1498141823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275059-natural-gas-inventory-builds-slightly-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory builds slightly more than expected</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>+61</strong>&nbsp;<strong>Bcf </strong>vs. +58 Bcf consensus, +78 Bcf last week.</li><li>Futures&nbsp;<font color='green'>+0.45%</font>&nbsp;to $2.906.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3275059\" data-linked=\"Natural gas inventory builds slightly more than expected\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory builds slightly more than expected https://seekingalpha.com/news/3275059-natural-gas-inventory-builds-slightly-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3275059-natural-gas-inventory-builds-slightly-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275058\" data-ts=\"1498141690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNK\" target=\"_blank\">CNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275058-cinemark-downgraded-leads-another-rough-session-for-theater-names\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cinemark downgraded, leads another rough session for theater names</a></h4><ul><li>Premium video-on-demand movie rentals could be \"right around the corner,\" says Credit Suisse's Omar Sheikh, downgrading Cinemark (<a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc'>CNK</a> <font color='red'>-3.9%</font>) to Underperform from Neutral. HIs $34 price target suggests more than&nbsp;<font color='red'>10% downside</font>.</li><li>Alongside, he trims price targets for AMC Entertainment (<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a> <font color='red'>-2.6%</font>) and Regal Entertainment (<a href='https://seekingalpha.com/symbol/RGC' title='Regal Entertainment Group'>RGC</a> <font color='red'>-2.1%</font>); AMC to $20 from $26, RGC to $17 from $19.</li><li>Other names include: IMAX (<a href='https://seekingalpha.com/symbol/IMAX' title='IMAX Corporation'>IMAX</a> <font color='red'>-1.9%</font>), National CineMedia (<a href='https://seekingalpha.com/symbol/NCMI' title='National CineMedia, Inc.'>NCMI</a> <font color='red'>-2.4%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274588-barclays-warns-second-half-u-s-box-office-slowdown\" target=\"_blank\">Barclays warns on second-half U.S box office slowdown</a> (June 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275058\" data-linked=\"Cinemark downgraded, leads another rough session for theater names\" data-tweet=\"$CNK $CNK $AMC - Cinemark downgraded, leads another rough session for theater names https://seekingalpha.com/news/3275058-cinemark-downgraded-leads-another-rough-session-for-theater-names?source=tweet\" data-url=\"https://seekingalpha.com/news/3275058-cinemark-downgraded-leads-another-rough-session-for-theater-names\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275057\" data-ts=\"1498141622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATUS\" target=\"_blank\">ATUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275057-altice-usa-comes-out-of-ipo-gate-up-6_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altice USA comes out of IPO gate up 6.5%</a></h4><ul>   <li>Altice USA (NYSE:<a href='https://seekingalpha.com/symbol/ATUS' title='Altice USA'>ATUS</a>) has opened for trading after <a href=\"https://seekingalpha.com/news/3274923-altice-usa-prices-initial-public-offering-30\" target=\"_blank\">pricing its initial public offering</a> last night.</li>    <li>Shares are trading at $31.96, <font color='green'>up 6.5%</font> after pricing at $30. The company raised nearly $2B in floating almost 64M shares.</li>    <li>Altice USA makes up U.S. holdings of Dutch firm Altice (<a href='https://seekingalpha.com/symbol/ATCEY' title='ALTICE S A ADR'>OTCPK:ATCEY</a>), which made a move into the U.S. market by buying Suddenlink Communications and Cablevision Systems.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275057\" data-linked=\"Altice USA comes out of IPO gate up 6.5%\" data-tweet=\"$ATUS $ATUS $ATCEY - Altice USA comes out of IPO gate up 6.5% https://seekingalpha.com/news/3275057-altice-usa-comes-out-of-ipo-gate-up-6_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3275057-altice-usa-comes-out-of-ipo-gate-up-6_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275055\" data-ts=\"1498141508\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STM\" target=\"_blank\">STM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275055-stmicroelectronics-announces-1_5b-bond-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STMicroelectronics announces $1.5B bond offering</a></h4><ul><li>        STMicroelectronics&rsquo; (NYSE:<a href='https://seekingalpha.com/symbol/STM' title='STMicroelectronics NV'>STM</a>) <a href=\"http://www.st.com/content/st_com/en/about/media-center/press-item.html/c2823.html\" target=\"_blank\">offers </a>$1.5B in convertible senior unsecured bonds into new or existing ordinary shares.</li><li>Early redemption of $600M in outstanding Zero Coupon Convertible Bonds due in 2019.</li><li>                  STMicroelectronics shares are&nbsp;<font color='red'>down 4.10%</font>.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3275055\" data-linked=\"STMicroelectronics announces $1.5B bond offering\" data-tweet=\"$STM - STMicroelectronics announces $1.5B bond offering https://seekingalpha.com/news/3275055-stmicroelectronics-announces-1_5b-bond-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3275055-stmicroelectronics-announces-1_5b-bond-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275054\" data-ts=\"1498141491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTO\" target=\"_blank\">PRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275054-proteon-secures-22m-capital-raise-funds-sufficient-to-complete-late-stage-study-of-lead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteon secures $22M capital raise, funds sufficient to complete late-stage study of lead candidate vonapitase; shares ahead 14%</a></h4><ul><li>Proteon Therapeutics (<a href='https://seekingalpha.com/symbol/PRTO' title='Proteon Therapeutics'>PRTO</a> <font color='green'>+13.5%</font>) inks an <a href=\"https://seekingalpha.com/pr/16869608-proteon-therapeutics-announces-22_0-million-private-placement\" target=\"_blank\">agreement </a>with a syndicate of institutional investors for the direct sale of 22K shares of Series A Convertible Preferred Stock at $1,000 per share yielding gross proceeds of $22M.</li><li>Series A shares will be convertible into 22,112,775 common shares, equating to a conversion price of $0.9949.</li><li>Net proceeds will fund the ongoing PATENCY-2 study and continued market access activities. The company says the funding will extend its cash runway into Q4 2019, allowing it to release top-line data from <a href=\"https://clinicaltrials.gov/ct2/show/NCT02414841?lead=proteon+Therapeutics&amp;phase=2&amp;rank=1\" target=\"_blank\">PATENCY-2</a>, a Phase 3 clinical trial assessing lead candidate vonapanitase for increasing the patency of the access fistula in hemodialysis patients.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275054\" data-linked=\"Proteon secures $22M capital raise, funds sufficient to complete late-stage study of lead candidate vonapitase; shares ahead 14%\" data-tweet=\"$PRTO - Proteon secures $22M capital raise, funds sufficient to complete late-stage study of lead candidate vonapitase; shares ahead 14% https://seekingalpha.com/news/3275054-proteon-secures-22m-capital-raise-funds-sufficient-to-complete-late-stage-study-of-lead?source=tweet\" data-url=\"https://seekingalpha.com/news/3275054-proteon-secures-22m-capital-raise-funds-sufficient-to-complete-late-stage-study-of-lead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275050\" data-ts=\"1498140390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDR\" target=\"_blank\">WDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275050-waddell-reed-up-nearly-4-on-acquisition-rumor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Waddell &amp; Reed up nearly 4% on acquisition rumor</a></h4><ul><li>Traditional asset management is a ripe sector for consolidation. There's already been some, and expect more. This morning, <a href=\"https://www.dealreporter.com/info/\" target=\"_blank\">Dealreporter</a> is speculating on Waddell &amp; Reed (<a href='https://seekingalpha.com/symbol/WDR' title='Waddell & Reed Financial Inc'>WDR</a> <font color='green'>+3.9%</font>) as maybe the next target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275050\" data-linked=\"Waddell &amp; Reed up nearly 4% on acquisition rumor\" data-tweet=\"$WDR - Waddell &amp; Reed up nearly 4% on acquisition rumor https://seekingalpha.com/news/3275050-waddell-reed-up-nearly-4-on-acquisition-rumor?source=tweet\" data-url=\"https://seekingalpha.com/news/3275050-waddell-reed-up-nearly-4-on-acquisition-rumor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275049\" data-ts=\"1498140264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AET\" target=\"_blank\">AET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275049-gop-healthcare-plan-to-provide-50b-to-stabilize-insurance-exchanges-insurers-rally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GOP healthcare plan to provide $50B to stabilize insurance exchanges, insurers rally</a></h4><ul><li>The complete draft of Republicans' healthcare bill is not due to be released for another hour, but Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2017-06-22/senate-gop-health-plan-said-to-add-billions-to-stabilize-markets?cmpid=socialflow-twitter-business&amp;utm_content=business&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_medium=social\" target=\"_blank\">reports </a>that it provides $50B over four years to stabilize insurance exchanges in addition to cost-sharing subsidy payments through 2019.</li><li>A person familiar with the plan said $15B will be earmarked for the next two years and $10B/year in 2020 and 2021.</li><li>It will also provide $62B over eight years to a state innovation fund that can be used to cover high-risk patients, reinsurance and other items. Obamacare's expansion of Medicaid would be phased out over three years starting in 2021.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GRX' title='The Gabelli Healthcare & Wellness Rx Trust'>GRX</a> <a href='https://seekingalpha.com/symbol/THW' title='Tekla World Healthcare Fund'>THW</a> <a href='https://seekingalpha.com/symbol/IXJ' title='iShares Global Healthcare ETF'>IXJ</a> <a href='https://seekingalpha.com/symbol/BME' title='BlackRock Health Sciences Trust'>BME</a> <a href='https://seekingalpha.com/symbol/IRY' title='SPDR S&P International Health Care Sector ETF'>IRY</a></li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color='green'>+0.1%</font>)(<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='green'>+1.3%</font>)</li><li><strong>Update</strong>: The bill provides tax credits to individuals up to 350% of the federal poverty level. <a href=\"https://www.budget.senate.gov/imo/media/doc/SENATEHEALTHCARE.pdf\" target=\"_blank\">Text of the bill</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275049\" data-linked=\"GOP healthcare plan to provide $50B to stabilize insurance exchanges, insurers rally\" data-tweet=\"$AET $GRX $THW - GOP healthcare plan to provide $50B to stabilize insurance exchanges, insurers rally https://seekingalpha.com/news/3275049-gop-healthcare-plan-to-provide-50b-to-stabilize-insurance-exchanges-insurers-rally?source=tweet\" data-url=\"https://seekingalpha.com/news/3275049-gop-healthcare-plan-to-provide-50b-to-stabilize-insurance-exchanges-insurers-rally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275047\" data-ts=\"1498140076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAH-OLD\" target=\"_blank\">PAH-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275047-report-blackstone-pay-4b-for-50-stake-in-platform-specialty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Blackstone could pay $4B for 50% stake in Platform Specialty</a></h4><ul><li>Platform Specialty Products (<a href='https://seekingalpha.com/symbol/PAH-OLD' title='Platform Specialty Products Corp'>PAH-OLD</a> <font color='green'>+5.6%</font>) opens with strong gains following a <em>NY&nbsp;Post</em> report that Blackstone (<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a> <font color='green'>+0.7%</font>) has formed a bidding consortium that <a href=\"http://nypost.com/2017/06/21/ackman-set-to-cash-in-as-blackstone-eyes-chemical-deal/\" target=\"_blank\">could offer more than $4B to buy a 50% stake</a> in the chemicals company.</li><li>PAH's somewhat struggling agriculture division has been on the sale block for months, and the company plans to ask for final bids in mid-July, according to the report.</li><li>Such a deal could prove a boon to Bill Ackman, whose Pershing Square hedge fund holds a 14.5% stake in PAH.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275047\" data-linked=\"Report: Blackstone could pay $4B for 50% stake in Platform Specialty\" data-tweet=\"$PAH-OLD $PAH-OLD $BX - Report: Blackstone could pay $4B for 50% stake in Platform Specialty https://seekingalpha.com/news/3275047-report-blackstone-pay-4b-for-50-stake-in-platform-specialty?source=tweet\" data-url=\"https://seekingalpha.com/news/3275047-report-blackstone-pay-4b-for-50-stake-in-platform-specialty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275031\" data-ts=\"1498137600\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275031-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/OVAS-OLD' title='OvaScience, Inc.'>OVAS-OLD</a> <font color='green'>+12%</font>&nbsp;on jobs <a href=\"https://seekingalpha.com/news/3274883-new-chief-ovascience-50-percent-jobs-cut-shares-3-percent-hours\" target=\"_blank\">cut</a>.</li><li><a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a> <font color='green'>+12%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3274877-oracle-beats-0_11-beats-revenue\" target=\"_blank\">beat</a>.</li><li><a href='https://seekingalpha.com/symbol/PAH-OLD' title='Platform Specialty Products Corp'>PAH-OLD</a> <font color='green'>+10%</font>.</li><li><a href='https://seekingalpha.com/symbol/SPLS' title='Staples, Inc.'>SPLS</a> <font color='green'>+6%</font>&nbsp;on advanced talks to <a href=\"https://seekingalpha.com/news/3274997-staples-maybe-worth-nearly-10-per-share-lbo-deutsche\" target=\"_blank\">buy</a> Sycamore Partners.</li><li><a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3275004-american-takes-qatari-interest\" target=\"_blank\">investment</a> by Qatar Airways.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275031\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$OVAS-OLD $ORCL $PAH-OLD - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3275031-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3275031-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275029\" data-ts=\"1498137427\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTGN\" target=\"_blank\">VTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275029-early-stage-studies-support-potential-of-vistagens-avminus-101-for-treatment-of-neuropathic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Early-stage studies support potential of VistaGen&#39;s AV-101 for the treatment of neuropathic pain; shares ahead 8% premarket</a></h4><ul><li>Thinly traded nano cap VistaGen (NASDAQ:<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16869365-vistagen-announces-peer-reviewed-publication-scandinavian-journal-pain-highlighting-orally\" target=\"_blank\">announcement </a>of results from two Phase 1 studies of AV-101, a potential candidate for the non-opioid treatment of neuropathic pain. The results were just published in the <em>Scandinavian Journal of Pain</em>.</li><li>The data showed AV-101 was safe and well-tolerated. The company says the data, together with encouraging results from four preclinical models of pain associated with tissue inflammation and nerve injury, support future Phase 2 studies.</li><li><a href=\"http://www.vistagen.com/?page_id=11\" target=\"_blank\">AV-101</a>&nbsp;is an orally available CNS prodrug that is converted in the brain by cells called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Astrocyte\" target=\"_blank\">astrocytes&nbsp;</a>into its active metabolite, 7-chlorokynurenic acid (7-CI-KYNA), a highly selective antagonist of certain receptors &#40;NMDA&#41;&nbsp;that play key roles in neurodegenerative diseases, epilepsy and neuropathic pain.</li><li>See important&nbsp;<a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275029\" data-linked=\"Early-stage studies support potential of VistaGen&#39;s AV-101 for the treatment of neuropathic pain; shares ahead 8% premarket\" data-tweet=\"$VTGN - Early-stage studies support potential of VistaGen&#39;s AV-101 for the treatment of neuropathic pain; shares ahead 8% premarket https://seekingalpha.com/news/3275029-early-stage-studies-support-potential-of-vistagens-avminus-101-for-treatment-of-neuropathic?source=tweet\" data-url=\"https://seekingalpha.com/news/3275029-early-stage-studies-support-potential-of-vistagens-avminus-101-for-treatment-of-neuropathic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275027\" data-ts=\"1498137320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275027-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a>&nbsp;<font color='red'>-28%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3274985-kamada-withdraws-european-marketing-application-aatd-candidate-another-clinical-trial-needed\" target=\"_blank\">withdrawing</a> European marketing application for AATD candidate.</li><li><a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a>&nbsp;<font color='red'>-18%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3274882-steelcase-misses-0_04-misses-revenue\" target=\"_blank\">Q1 earnings</a> miss.</li><li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16869498-dryships-inc-reports-updated-key-financial-information-post-reverse-stock-split\" target=\"_blank\">updating</a> financial information post reverse stock split.</li><li><a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a> <font color='red'>-11%</font>.</li><li><a href='https://seekingalpha.com/symbol/JCAP' title='Jernigan Capital'>JCAP</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3274879-capital-raise-jernigan-capital\" target=\"_blank\">announcing</a> public offering of 3M shares of common stock.</li><li><a href='https://seekingalpha.com/symbol/SINA' title='Sina Corporation'>SINA</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/AVXS' title='AveXis'>AVXS</a> <font color='red'>-8%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3275027\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$KMDA $SCS $DRYS - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3275027-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3275027-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275024\" data-ts=\"1498136818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMHC\" target=\"_blank\">TMHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275024-taylor-morrison-down-3_7-after-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Taylor Morrison down 3.7% after share sale</a></h4><ul><li>The builder <a href=\"https://seekingalpha.com/filing/3601762\" target=\"_blank\">is selling 10M shares</a>, proceeds of which will be used to cash out backers' stakes.</li><li>Alongside the offering, preliminary results show the average sales pace per community for the two months ended May 31 at 2.9 homes per month vs. 2.2 homes in the same period a year earlier. Net sales orders for the two months ended May 31 were 1,736, up 24.3% Y/Y. Sales orders for the quarter ended June 30 should be about 1.8K.</li><li><a href='https://seekingalpha.com/symbol/TMHC' title='Taylor Morrison'>TMHC</a> -3.7% premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3275024\" data-linked=\"Taylor Morrison down 3.7% after share sale\" data-tweet=\"$TMHC - Taylor Morrison down 3.7% after share sale https://seekingalpha.com/news/3275024-taylor-morrison-down-3_7-after-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3275024-taylor-morrison-down-3_7-after-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275019\" data-ts=\"1498136410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275019-barnes-nobleplus-3-fq4-earnings-revenues-beat-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble +3% as FQ4 earnings, revenues beat estimates</a></h4><ul><li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>)&nbsp;<font color='green'>+3.1%</font> premarket after reporting a smaller than expected <a href=\"https://seekingalpha.com/news/3275010-barnes-and-noble-beats-0_04-beats-revenue\" target=\"_blank\">FQ4 loss</a> and beating revenue expectations.</li><li>BKS says comparable store sales fell 6.3% for both Q4 and the full year, but online sales rose 2.9% for the quarter and 3.7% for the full year.</li><li>BKS says FY 2017 was a challenging year but it reduced costs by $137M, \"enabling us to  sustain our profitability level\" - shares have dropped 42% YTD.</li><li>For FY 2018, BKS expects comparable bookstore sales to  decline in the low single digits with full year consolidated EBITDA of ~$180M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275019\" data-linked=\"Barnes &amp; Noble +3% as FQ4 earnings, revenues beat estimates\" data-tweet=\"$BKS - Barnes &amp; Noble +3% as FQ4 earnings, revenues beat estimates https://seekingalpha.com/news/3275019-barnes-nobleplus-3-fq4-earnings-revenues-beat-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3275019-barnes-nobleplus-3-fq4-earnings-revenues-beat-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275018\" data-ts=\"1498136286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMPI\" target=\"_blank\">DMPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275018-delmar-on-go-to-start-late-stage-study-of-lead-product-candidate-valminus-083-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DelMar on go to start late-stage study of lead product candidate VAL-083; shares ahead 8% premarket</a></h4><ul><li>Thinly traded nano cap DelMar Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16869366-delmar-pharmaceuticals-receives-institutional-review-board-approval-pivotal-phase-3-clinical\" target=\"_blank\">announcement </a>that it has received Institutional Review Board &#40;IRB&#41; approval to conduct a Phase 3 clinical trial assessing VAL-083 (dianhydrogalactitol) in patients with glioblastoma who failed to respond to treatment with a combination a temozolomide and Roche's Avastin (bevacizumab).</li><li>The study, called STAR-3, will enroll up to 180 subjects across 25 sites. Participants will receive either VAL-083 or investigator's choice of salvage therapy. The primary endpoint is overall survival.</li><li><a href=\"http://www.delmarpharma.com/pipeline.html\" target=\"_blank\">VAL-083</a>&nbsp;is a small molecule chemotherapeutic, specifically a bi-functional alkylating agent.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3242861-delmars-phase-2-study-assessing-valminus-083-brain-cancer-underway-shares-3-percent\" target=\"_blank\">DelMar's Phase 2 study assessing VAL-083 in brain cancer underway; shares up 3%</a> (Feb. 13)</li><li>See important&nbsp;<a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275018\" data-linked=\"DelMar on go to start late-stage study of lead product candidate VAL-083; shares ahead 8% premarket\" data-tweet=\"$DMPI - DelMar on go to start late-stage study of lead product candidate VAL-083; shares ahead 8% premarket https://seekingalpha.com/news/3275018-delmar-on-go-to-start-late-stage-study-of-lead-product-candidate-valminus-083-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3275018-delmar-on-go-to-start-late-stage-study-of-lead-product-candidate-valminus-083-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275017\" data-ts=\"1498136010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMGTY\" target=\"_blank\">IMGTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275017-former-apple-supplier-imagination-technologies-goes-up-for-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Former Apple supplier Imagination Technologies goes up for sale</a></h4><ul><li>        British chipmaker Imagination Technologies (<a href='https://seekingalpha.com/symbol/IMGTY' title='Imagination Technology Group PLC ADR'>OTC:IMGTY</a>) goes <a href=\"http://www.reuters.com/article/us-imagination-tech-apple-sale-idUSKBN19D0H8\" target=\"_blank\">up for sale</a> after Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) ditched the company&rsquo;s graphic chips for in-house designs. Apple accounts for half of Imagination&rsquo;s sales.</li><li>        In April, Apple made its supply change announcement that is effective within two years. Imagination Technologies shares immediately plummeted.</li><li>               Rumored interested buyers include Qualcomm, Mediatek, and Apple.&nbsp;</li><li>               Imagination had already put its embedded MIPS tech division and mobile connectivity division up for sale. The company now says it has received proposals for both divisions.&nbsp;</li><li>Imagination Technologies shares are&nbsp;<font color='green'>up 16.8%</font>, putting the market cap at $410M. &nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3255318-imagination-technologies-takeover-target\" target=\"_blank\">Imagination Technologies - a takeover target?</a> (April 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275017\" data-linked=\"Former Apple supplier Imagination Technologies goes up for sale\" data-tweet=\"$IMGTY $IMGTY $AAPL - Former Apple supplier Imagination Technologies goes up for sale https://seekingalpha.com/news/3275017-former-apple-supplier-imagination-technologies-goes-up-for-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3275017-former-apple-supplier-imagination-technologies-goes-up-for-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275016\" data-ts=\"1498135791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275016-jd-com-invests-397m-in-e-commerce-platform-farfetch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com invests $397M in e-commerce platform Farfetch</a></h4><ul><li>JD.com (NASDAQ:<a href='https://seekingalpha.com/symbol/JD' title='JD.com'>JD</a>) <font color='red'>-1.5%</font> premarket after <a href=\"https://seekingalpha.com/pr/16868977-jd-com-farfetch-partner-open-ultimate-gateway-bringing-luxury-brands-china\" target=\"_blank\">paying $397M for a stake</a> in fashion retailer Farfetch, which the companies say \"allows Chinese consumers to access  Farfetch's unique curation of the best luxury brands online.\"</li><li>JD will become one of the largest shareholders of Farfetch, and  JD&nbsp;CEO Richard Liu will join the Farfetch board.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275016\" data-linked=\"JD.com invests $397M in e-commerce platform Farfetch\" data-tweet=\"$JD - JD.com invests $397M in e-commerce platform Farfetch https://seekingalpha.com/news/3275016-jd-com-invests-397m-in-e-commerce-platform-farfetch?source=tweet\" data-url=\"https://seekingalpha.com/news/3275016-jd-com-invests-397m-in-e-commerce-platform-farfetch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275015\" data-ts=\"1498135367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275015-trovagene-inks-deal-unnamed-biopharma-firm-for-ctdna-tests-shares-ahead-32-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene inks deal with unnamed biopharma firm for ctDNA tests; shares ahead 32% premarket</a></h4><ul><li>Nano cap Trovagene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) jumps&nbsp;<font color='green'>32%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16869215-trovagene-announces-agreement-global-biopharmaceutical-company-utilize-trovera-ctdna-tests\" target=\"_blank\">announcement </a>that it has entered into an agreement with a global biopharma company to provide Trovera urine circulating tumor DNA (ctDNA) biomarker tests and services for use in its clinical trials.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275015\" data-linked=\"Trovagene inks deal with unnamed biopharma firm for ctDNA tests; shares ahead 32% premarket\" data-tweet=\"$TROV - Trovagene inks deal with unnamed biopharma firm for ctDNA tests; shares ahead 32% premarket https://seekingalpha.com/news/3275015-trovagene-inks-deal-unnamed-biopharma-firm-for-ctdna-tests-shares-ahead-32-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3275015-trovagene-inks-deal-unnamed-biopharma-firm-for-ctdna-tests-shares-ahead-32-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275011\" data-ts=\"1498134761\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRRX\" target=\"_blank\">DRRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275011-durect-completes-enrollment-in-late-stage-study-of-non-opioid-analgesic-shares-ahead-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DURECT completes enrollment in late-stage study of non-opioid analgesic; shares ahead 1% premarket</a></h4><ul><li>DURECT (NASDAQ:<a href='https://seekingalpha.com/symbol/DRRX' title='Durect Corporation'>DRRX</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16869117-durect-completes-enrollment-persist-phase-3-trial-posimir\" target=\"_blank\">announcement </a>that enrollment has been completed in the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02574520?term=durect&amp;titles=persist&amp;phase=2&amp;rank=1\" target=\"_blank\">PERSIST</a> trial evaluating POSIMIR (SABER-Bupivacaine) for the local treatment of post-operative pain.</li><li>The primary endpoint is pain intensity 48 hours after dosing as measured by a scale called NPRS-11 when patients sit up from a supine position. According to ClinicalTrials.gov, the final data collection date for the primary outcome measure is August. Top-line results should be available in Q4.</li><li>Novartis' Sandoz unit will commercialize in the U.S.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3264484-durect-novartis-sign-293m-u-s-development-marketing-deal-posimir\" target=\"_blank\">Durect, Novartis sign $293M U.S. development, marketing deal for Posimir</a> (May 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275011\" data-linked=\"DURECT completes enrollment in late-stage study of non-opioid analgesic; shares ahead 1% premarket\" data-tweet=\"$DRRX - DURECT completes enrollment in late-stage study of non-opioid analgesic; shares ahead 1% premarket https://seekingalpha.com/news/3275011-durect-completes-enrollment-in-late-stage-study-of-non-opioid-analgesic-shares-ahead-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3275011-durect-completes-enrollment-in-late-stage-study-of-non-opioid-analgesic-shares-ahead-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275004\" data-ts=\"1498134189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAL\" target=\"_blank\">AAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275004-american-takes-off-on-qatari-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American takes off on Qatari interest</a></h4><ul><li>American Airlines (NASDAQ:<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a>) <font color='green'>+5.5%</font> premarket after Qatar Airways indicated its intention to make a \"significant investment\" in the carrier on the open market.</li><li>The proposed investment was not solicited and would in no way change the company's board composition, governance, management or strategic direction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275004\" data-linked=\"American takes off on Qatari interest\" data-tweet=\"$AAL - American takes off on Qatari interest https://seekingalpha.com/news/3275004-american-takes-off-on-qatari-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3275004-american-takes-off-on-qatari-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275003\" data-ts=\"1498133893\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESNC\" target=\"_blank\">ESNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275003-ensyncminus-29-on-news-of-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnSync -29% on news of public offering</a></h4><ul>     <li>EnSync (NYSEMKT:<a href='https://seekingalpha.com/symbol/ESNC' title='EnSync, Inc.'>ESNC</a>) <font color='red'>-29.4%</font> premarket after announcing a proposed <a href=\"https://seekingalpha.com/pr/16868779-ensync-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering</a> of common stock; the size is not disclosed.</li><li>ESNC says it plans to use the proceeds to fund the  development of  distributed energy resource projects, for working capital and   general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275003\" data-linked=\"EnSync -29% on news of public offering\" data-tweet=\"$ESNC - EnSync -29% on news of public offering https://seekingalpha.com/news/3275003-ensyncminus-29-on-news-of-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3275003-ensyncminus-29-on-news-of-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3274997\" data-ts=\"1498133216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLS\" target=\"_blank\">SPLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3274997-staples-maybe-worth-nearly-10-per-share-in-lbo-deutsche\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Staples maybe worth nearly $10 per share in LBO - Deutsche</a></h4><ul><li>A buyout price in the high $9 per share area - or just over $9B - would work if the new owner can lift margins by 25 basis points per year, says analyst Mike Baker. Over time, this would move EBITDA margin to 8.5% by 2021 vs. 7.5% estimated for this year.</li><li>Source: Bloomberg</li><li>Staples (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLS' title='Staples, Inc.'>SPLS</a>) is&nbsp;<font color='green'>up 7.5%</font>&nbsp;premarket to $9.31 after <a href=\"https://seekingalpha.com/news/3274928-reuters-sycamore-partners-near-deal-acquire-staples\" target=\"_blank\">last night's report of</a> talks between it and P-E player Sycamore Partners.</li></ul><div class=\"tiny-share-widget\" data-id=\"3274997\" data-linked=\"Staples maybe worth nearly $10 per share in LBO - Deutsche\" data-tweet=\"$SPLS - Staples maybe worth nearly $10 per share in LBO - Deutsche https://seekingalpha.com/news/3274997-staples-maybe-worth-nearly-10-per-share-in-lbo-deutsche?source=tweet\" data-url=\"https://seekingalpha.com/news/3274997-staples-maybe-worth-nearly-10-per-share-in-lbo-deutsche\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3274985\" data-ts=\"1498132397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMDA\" target=\"_blank\">KMDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3274985-kamada-withdraws-european-marketing-application-for-aatd-candidate-another-clinical-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kamada withdraws European marketing application for AATD candidate, another clinical trial needed; shares down 25% premarket</a></h4><ul><li>Kamada Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a>) slumps&nbsp;<font color='red'>25%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/filing/3601779\" target=\"_blank\">announcement </a>that it has withdrawn its marketing application in Europe seeking approval of its inhaled Alpha-1 Antitrypsin &#40;AAT&#41; therapy for the treatment of Alpha-1 Antitrypsin Deficiency &#40;AATD&#41;. The company took action after the European Medicines Agency &#40;EMA&#41; indicated that more data are needed, specifically another clinical trial, before it will accept the filing for review. The EMA believed that the post-hoc data submitted by the company was insufficient to prove the efficacy of inhaled AAT.</li><li>Kamada is currently working with the U.S. FDA to secure approval to initiate a Phase 3 study that is expected to begin next year. It intends to use these results to support the resubmission of its European application.</li><li>CEO Amir London says, &ldquo;While we are disappointed that the withdrawal of our MAA extends the timeline for the potential approval of inhaled AAT for AATD in Europe, we remain committed to the continued development of this product. Based on the successful U.S. Phase 2 study concluded late last year and the positive lung function data from the European Phase 2/3 studies, we believe that inhaled AAT has the potential to be a safe and effective treatment for AATD, an area with significant unmet medical need.&nbsp; We appreciate the strong support we continue to receive from patients and clinicians, as well as the transparent discussions with the EMA, and look forward to moving ahead with a U.S. Phase 3 pivotal clinical trial, once approved, as expeditiously as possible, which would allow us to&nbsp;utilize the supplementary data&nbsp;to be obtained from that study in order to resubmit our MAA to the EMA at an appropriate time thereafter.&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"3274985\" data-linked=\"Kamada withdraws European marketing application for AATD candidate, another clinical trial needed; shares down 25% premarket\" data-tweet=\"$KMDA - Kamada withdraws European marketing application for AATD candidate, another clinical trial needed; shares down 25% premarket https://seekingalpha.com/news/3274985-kamada-withdraws-european-marketing-application-for-aatd-candidate-another-clinical-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3274985-kamada-withdraws-european-marketing-application-for-aatd-candidate-another-clinical-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3274987\" data-ts=\"1498131909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3274987-analysts-raise-oracle-price-targets-after-stellar-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts raise Oracle price targets after stellar earnings</a></h4><ul><li>        Stifel raises Oracle&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) price target to $52 from $47 while maintaining a Buy rating. Analyst Brad Reback cites the Q4 beat, continued transition to the cloud, and strong SaaS and PaaS market positions.</li><li>               BTIG raises price target from $47 to $58 and maintains Buy. Analyst raises FY18 EPS estimate to $2.85 to $3.05.&nbsp;</li><li>           JPMorgan pushes price target up $4 to $55 and maintains Overweight rating. Raises FY18 EPS estimate two cents to $2.92 and reiterates FY19 EPS estimate of $3.13.  </li><li>        Source: <a href=\"https://www.streetinsider.com/stock_lookup.php?LookUp=Get+Quote&amp;q=ORCL\" target=\"_blank\">StreetInsider</a></li><li>Oracle shares are&nbsp;<font color='green'>up 10.92%&nbsp;</font>premarket to $51.39.&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274887-oracle-saas-q4-sales-75-percent-expects-fy18-arr-rev-2b-7_9-percent\" target=\"_blank\">Oracle SaaS Q4 sales up 75%, expects FY18 ARR rev over $2B; up 7.9%</a> (June 21)</li></ul> &nbsp;<br /><div class=\"tiny-share-widget\" data-id=\"3274987\" data-linked=\"Analysts raise Oracle price targets after stellar earnings\" data-tweet=\"$ORCL - Analysts raise Oracle price targets after stellar earnings https://seekingalpha.com/news/3274987-analysts-raise-oracle-price-targets-after-stellar-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3274987-analysts-raise-oracle-price-targets-after-stellar-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3274986\" data-ts=\"1498131856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUV\" target=\"_blank\">LUV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3274986-southwest-air-up-1-after-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southwest Air up more than 1% after upgrade</a></h4><ul><li>The big run continues for Southwest Airlines (NYSE:<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a>) after Argus analyst David Coleman upgrades to Buy from Hold. His $68 price target is&nbsp;<font color='green'>11% above&nbsp;</font>yesterday's close.</li><li>Shares are already&nbsp;<font color='green'>up 22.5%</font>&nbsp;YTD, and they're&nbsp;<font color='green'>higher by another 1.2%</font>&nbsp;in premarket action to $61.76.</li></ul><div class=\"tiny-share-widget\" data-id=\"3274986\" data-linked=\"Southwest Air up more than 1% after upgrade\" data-tweet=\"$LUV - Southwest Air up more than 1% after upgrade https://seekingalpha.com/news/3274986-southwest-air-up-1-after-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3274986-southwest-air-up-1-after-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3274981\" data-ts=\"1498131052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACN\" target=\"_blank\">ACN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3274981-accenture-beats-rev-estimate-lowers-guidance-shares-down-1_25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Accenture beats rev estimate, lowers guidance; shares down 1.25%</a></h4><ul><li>        Accenture (NYSE:<a href='https://seekingalpha.com/symbol/ACN' title='Accenture plc'>ACN</a>) reports Q3 results with a revenue beat and EPS in-line with estimates. New bookings were $9.8B, breaking down into $5.2B in consulting bookings, up 4% on the year, and $4.6B in outsourcing bookings, up 6%.</li><li>               Half of Q3 revenues came from what Accenture calls &ldquo;The New,&rdquo; which includes digital, cloud, and security services.&nbsp;</li><li>                  Charge: The quarter included a $510M pension settlement that took $0.47 off EPS.    </li><li>                  Cash: OCF reported at $1.79B, FCF at $1.66B, and the total cash balance was $3.4B as of May 31.    </li><li>               Q4 guidance: Revenue up 5% to 8% between $8.85B and $9.10B, which straddles the $8.93B consensus estimate.&nbsp;</li><li>               FY17 guidance: Revenue growth of 6% to 7%, lowered from the previous range of 6% to 8%. Accenture lowers EPS guidance from $5.70 to $5.87, which would beat the $5.86 consensus, to between $5.37 and $5.44 including the pension settlement.&nbsp;</li><li><a href=\"https://seekingalpha.com/pr/16869098-accenture-reports-strong-third-quarter-fiscal-2017-results\" target=\"_blank\">               Press release&nbsp;</a></li><li>        Accenture shares are&nbsp;<font color='red'>down 1.25%</font>&nbsp;premarket.&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274973-accenture-eps-line-beats-revenue\" target=\"_blank\">Accenture EPS in-line, beats on revenue</a> (June 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3274981\" data-linked=\"Accenture beats rev estimate, lowers guidance; shares down 1.25%\" data-tweet=\"$ACN - Accenture beats rev estimate, lowers guidance; shares down 1.25% https://seekingalpha.com/news/3274981-accenture-beats-rev-estimate-lowers-guidance-shares-down-1_25?source=tweet\" data-url=\"https://seekingalpha.com/news/3274981-accenture-beats-rev-estimate-lowers-guidance-shares-down-1_25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3274979\" data-ts=\"1498130666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3274979-ema-accepts-shires-marketing-application-for-recombinant-therapy-for-inherited-bleeding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EMA accepts Shire&#39;s marketing application for recombinant therapy for inherited bleeding disorder; shares ahead 2% premarket</a></h4><ul><li>Shire plc (NASDAQ:<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume after it <a href=\"https://seekingalpha.com/pr/16868961-shire-announces-ema-validation-veyvondi-tm-von-willebrand-factor-recombinant-marketing\" target=\"_blank\">announced </a>that the European Medicines Agency &#40;EMA&#41; has accepted for review its marketing application seeking approval of VEYVONDI [von Willebrand factor (Recombinant)] for the on-demand treatment and control of bleeding episodes of adults with von Willebrand disease, an inherited bleeding disorder.</li><li>The product is currently marketed in the U.S. under the brand name <a href=\"http://www.vonvendi.com/\" target=\"_blank\">VONVENDI</a>, approved by the FDA in December 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3274979\" data-linked=\"EMA accepts Shire&#39;s marketing application for recombinant therapy for inherited bleeding disorder; shares ahead 2% premarket\" data-tweet=\"$SHPG - EMA accepts Shire&#39;s marketing application for recombinant therapy for inherited bleeding disorder; shares ahead 2% premarket https://seekingalpha.com/news/3274979-ema-accepts-shires-marketing-application-for-recombinant-therapy-for-inherited-bleeding?source=tweet\" data-url=\"https://seekingalpha.com/news/3274979-ema-accepts-shires-marketing-application-for-recombinant-therapy-for-inherited-bleeding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3274972\" data-ts=\"1498129478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIN\" target=\"_blank\">HAIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3274972-on-hain-celestials-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Hain Celestial&#39;s Q3</a></h4><ul>     <li>Hain Celestial (NASDAQ:<a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a>) reports revenue declined 4.1% in <a href=\"https://seekingalpha.com/pr/16869052-hain-celestial-announces-financial-results-expands-strategic-plan-deliver-enhanced\" target=\"_blank\">Q3</a>.</li>     <li>Segment sales: United States: $308.54M (-5.2%); United Kingdom: $181.94M (-11.7%); Hain Pure Protein: $117.77M (+4.9%); Rest of World: $98.32M (+5.8%).</li>     <li>Gross margin rate fell 140 bps to 20.3%.</li>     <li>Adjusted operating margin rate squeezed 290 bps to 8%.</li>     <li><b>Q4 Guidance</b>:&nbsp;Net sales: $715M to $735M; Adjusted EBITDA: $80M to $ 85M; Diluted EPS: $0.40 to $0.43.</li>     <li><b>FY2017 Guidance</b>: Net sales: $2.84B to $2.86B; Adjusted EBITDA: $270M to $275M; Diluted EPS: $1.19 to $1.22.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3274972\" data-linked=\"More on Hain Celestial&#39;s Q3\" data-tweet=\"$HAIN - More on Hain Celestial&#39;s Q3 https://seekingalpha.com/news/3274972-on-hain-celestials-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3274972-on-hain-celestials-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:04 AM </div></div></li>","count":62,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}